Direct and Indirect Effectiveness of Influenza Vaccination Delivered to Children at School Preceding an Epidemic Caused by 3 New Influenza Virus Variants
Open Access
- 1 December 2010
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 202 (11) , 1626-1633
- https://doi.org/10.1086/657089
Abstract
Background. Influenza is an uncontrolled epidemic disease that is vaccine preventable. New recommendations for universal immunization present a challenge to the implementation of vaccine delivery. This field trial examines the effectiveness of school-based clinics for vaccine delivery before an epidemic caused by 3 new influenza virus variants not contained in the vaccine. Methods. Live attenuated influenza vaccine (LAIV) was offered to eligible children in elementary schools of eastern Bell County, Texas. Age-specific rates of medically attended acute respiratory illness for health plan members at the intervention site were compared with those for members at comparison sites during the epidemic, defined by viral surveillance at all sites. Results. Almost 48% of children in elementary schools were vaccinated. Significant herd protection attributed to LAIV was detected for all age groups except 12–17-year-old students, who were not offered free vaccine. Approximately 2500 medical encounters were prevented at the intervention site. Inactivated vaccine provided marginal protection against the epidemic viruses. Conclusions. LAIV delivered to elementary-school children before an epidemic caused by 3 new variant influenza viruses generated significant cross-protection for the recipients and indirect (herd) protection for the community. Trial registration. ClinicalTrials.gov identifier: NCT00138294.Keywords
This publication has 30 references indexed in Scilit:
- Antibody response to influenza vaccination in the elderly: A quantitative reviewVaccine, 2006
- Influenza-Associated Deaths among Children in the United States, 2003–2004New England Journal of Medicine, 2005
- Live Attenuated Influenza Vaccine, Trivalent, Is Safe in Healthy Children 18 Months to 4 Years, 5 to 9 Years, and 10 to 18 Years of Age in a Community-Based, Nonrandomized, Open-Label TrialPediatrics, 2005
- Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in childrenVaccine, 2005
- Influenza-Associated Hospitalizations in the United StatesJAMA, 2004
- Direct and Total Effectiveness of the Intranasal, Live-Attenuated, Trivalent Cold-Adapted Influenza Virus Vaccine Against the 2000-2001 Influenza A(H1N1) and B Epidemic in Healthy ChildrenArchives of Pediatrics & Adolescent Medicine, 2004
- Estimating Efficacy of Trivalent, Cold-adapted, Influenza Virus Vaccine (CAIV-T) against Influenza A (H1N1) and B Using Surveillance CulturesAmerican Journal of Epidemiology, 2003
- A computerized reminder strategy is effective for annual influenza immunization of children with asthma or reactive airway diseaseThe Pediatric Infectious Disease Journal, 2001
- Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccineThe Journal of Pediatrics, 2000
- Emerging Infections: Pandemic InfluenzaEpidemiologic Reviews, 1996